Report Cover

Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026


The Devic's Syndrome (Neuromyelitis Optica) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Devic's Syndrome (Neuromyelitis Optica) Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Devic's Syndrome (Neuromyelitis Optica) Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Devic's Syndrome (Neuromyelitis Optica) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Eculizumab
    Methylprednisolone
    Azathioprine
    Mycophenolate Mofetil
    Rituximab

Market segment by Application, can be divided into
    Hospitals
    Clinic
    Others

Market segment by players, this report covers
    Alexion Pharmaceuticals, Inc.
    Teva Pharmaceuticals
    Fresenius Kabi AG
    Pharmacia & Upjohn (a subsidary of Pfizer)
    Lupin Ltd.
    Sagent Pharmaceuticals, Inc.
    Zydus Pharmaceuticals, Inc.
    Sandoz Inc. (Novartis)
    Alkem Laboratories Ltd.
    Mylan Pharmaceuticals, Inc.
    Hoffmann-La Roche/ Chugai Pharmaceutical
    MedImmune LLC
    RemeGen, Ltd.

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
    1.1 Product Overview and Scope of Devic's Syndrome (Neuromyelitis Optica) Treatment
    1.2 Classification of Devic's Syndrome (Neuromyelitis Optica) Treatment by Type
        1.2.1 Overview: Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type in 2020
        1.2.3 Eculizumab
        1.2.4 Methylprednisolone
        1.2.5 Azathioprine
        1.2.6 Mycophenolate Mofetil
        1.2.7 Rituximab
    1.3 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market by Application
        1.3.1 Overview: Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Hospitals
        1.3.3 Clinic
        1.3.4 Others
    1.4 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size & Forecast
    1.5 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast by Region
        1.5.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Region, (2016-2021)
        1.5.3 North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2016-2026)
        1.5.4 Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2016-2026)
        1.5.6 South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Devic's Syndrome (Neuromyelitis Optica) Treatment Market Drivers
        1.6.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Market Restraints
        1.6.3 Devic's Syndrome (Neuromyelitis Optica) Treatment Trends Analysis
2 Company Profiles
    2.1 Alexion Pharmaceuticals, Inc.
        2.1.1 Alexion Pharmaceuticals, Inc. Details
        2.1.2 Alexion Pharmaceuticals, Inc. Major Business
        2.1.3 Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.1.4 Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 Alexion Pharmaceuticals, Inc. Recent Developments and Future Plans
    2.2 Teva Pharmaceuticals
        2.2.1 Teva Pharmaceuticals Details
        2.2.2 Teva Pharmaceuticals Major Business
        2.2.3 Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.2.4 Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 Teva Pharmaceuticals Recent Developments and Future Plans
    2.3 Fresenius Kabi AG
        2.3.1 Fresenius Kabi AG Details
        2.3.2 Fresenius Kabi AG Major Business
        2.3.3 Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.3.4 Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 Fresenius Kabi AG Recent Developments and Future Plans
    2.4 Pharmacia & Upjohn (a subsidary of Pfizer)
        2.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Details
        2.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Major Business
        2.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Developments and Future Plans
    2.5 Lupin Ltd.
        2.5.1 Lupin Ltd. Details
        2.5.2 Lupin Ltd. Major Business
        2.5.3 Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.5.4 Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 Lupin Ltd. Recent Developments and Future Plans
    2.6 Sagent Pharmaceuticals, Inc.
        2.6.1 Sagent Pharmaceuticals, Inc. Details
        2.6.2 Sagent Pharmaceuticals, Inc. Major Business
        2.6.3 Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.6.4 Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 Sagent Pharmaceuticals, Inc. Recent Developments and Future Plans
    2.7 Zydus Pharmaceuticals, Inc.
        2.7.1 Zydus Pharmaceuticals, Inc. Details
        2.7.2 Zydus Pharmaceuticals, Inc. Major Business
        2.7.3 Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.7.4 Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 Zydus Pharmaceuticals, Inc. Recent Developments and Future Plans
    2.8 Sandoz Inc. (Novartis)
        2.8.1 Sandoz Inc. (Novartis) Details
        2.8.2 Sandoz Inc. (Novartis) Major Business
        2.8.3 Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.8.4 Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 Sandoz Inc. (Novartis) Recent Developments and Future Plans
    2.9 Alkem Laboratories Ltd.
        2.9.1 Alkem Laboratories Ltd. Details
        2.9.2 Alkem Laboratories Ltd. Major Business
        2.9.3 Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.9.4 Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Alkem Laboratories Ltd. Recent Developments and Future Plans
    2.10 Mylan Pharmaceuticals, Inc. 
        2.10.1 Mylan Pharmaceuticals, Inc. Details
        2.10.2 Mylan Pharmaceuticals, Inc. Major Business
        2.10.3 Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.10.4 Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 Mylan Pharmaceuticals, Inc. Recent Developments and Future Plans
    2.11 Hoffmann-La Roche/ Chugai Pharmaceutical
        2.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Details
        2.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Major Business
        2.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Developments and Future Plans
    2.12 MedImmune LLC
        2.12.1 MedImmune LLC Details
        2.12.2 MedImmune LLC Major Business
        2.12.3 MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.12.4 MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.12.5 MedImmune LLC Recent Developments and Future Plans
    2.13 RemeGen, Ltd.
        2.13.1 RemeGen, Ltd. Details
        2.13.2 RemeGen, Ltd. Major Business
        2.13.3 RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
        2.13.4 RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019-2021)
        2.13.5 RemeGen, Ltd. Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Devic's Syndrome (Neuromyelitis Optica) Treatment Players Market Share
        3.2.2 Top 10 Devic's Syndrome (Neuromyelitis Optica) Treatment Players Market Share
        3.2.3 Market Competition Trend
    3.3 Devic's Syndrome (Neuromyelitis Optica) Treatment Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Market Share by Type (2016-2021)
    4.2 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
    5.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2016-2021)
    5.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
    6.1 North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2026)
    6.2 North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2026)
    6.3 North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
        6.3.1 North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2016-2026)
        6.3.2 United States Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        6.3.3 Canada Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        6.3.4 Mexico Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
    7.1 Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2026)
    7.2 Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2026)
    7.3 Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
        7.3.1 Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2016-2026)
        7.3.2 Germany Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        7.3.3 France Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        7.3.5 Russia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        7.3.6 Italy Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2026)
    8.2 Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2026)
    8.3 Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Region
        8.3.1 Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Region (2016-2026)
        8.3.2 China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        8.3.3 Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        8.3.4 South Korea Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        8.3.5 India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        8.3.7 Australia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
    9.1 South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2026)
    9.2 South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2026)
    9.3 South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
        9.3.1 South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2016-2026)
        9.3.2 Brazil Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        9.3.3 Argentina Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2026)
    10.2 Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2026)
    10.3 Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
        10.3.1 Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2016-2026)
        10.3.2 Turkey Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
        10.3.4 UAE Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

List of Tables Table 1. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026 Table 2. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026 Table 3. Global Market Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026) Table 4. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) by Region (2016-2021) Table 5. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Region (2021-2026) Table 6. Alexion Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors Table 7. Alexion Pharmaceuticals, Inc. Major Business Table 8. Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 9. Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 10. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors Table 11. Teva Pharmaceuticals Major Business Table 12. Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 13. Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 14. Fresenius Kabi AG Corporate Information, Head Office, and Major Competitors Table 15. Fresenius Kabi AG Major Business Table 16. Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 17. Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 18. Pharmacia & Upjohn (a subsidary of Pfizer) Corporate Information, Head Office, and Major Competitors Table 19. Pharmacia & Upjohn (a subsidary of Pfizer) Major Business Table 20. Pharmacia & Upjohn (a subsidary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 21. Pharmacia & Upjohn (a subsidary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 22. Lupin Ltd. Corporate Information, Head Office, and Major Competitors Table 23. Lupin Ltd. Major Business Table 24. Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 25. Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 26. Sagent Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors Table 27. Sagent Pharmaceuticals, Inc. Major Business Table 28. Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 29. Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 30. Zydus Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors Table 31. Zydus Pharmaceuticals, Inc. Major Business Table 32. Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 33. Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 34. Sandoz Inc. (Novartis) Corporate Information, Head Office, and Major Competitors Table 35. Sandoz Inc. (Novartis) Major Business Table 36. Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 37. Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 38. Alkem Laboratories Ltd. Corporate Information, Head Office, and Major Competitors Table 39. Alkem Laboratories Ltd. Major Business Table 40. Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 41. Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 42. Mylan Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors Table 43. Mylan Pharmaceuticals, Inc. Major Business Table 44. Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 45. Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 46. Hoffmann-La Roche/ Chugai Pharmaceutical Corporate Information, Head Office, and Major Competitors Table 47. Hoffmann-La Roche/ Chugai Pharmaceutical Major Business Table 48. Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 49. Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 50. MedImmune LLC Corporate Information, Head Office, and Major Competitors Table 51. MedImmune LLC Major Business Table 52. MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 53. MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 54. RemeGen, Ltd. Corporate Information, Head Office, and Major Competitors Table 55. RemeGen, Ltd. Major Business Table 56. RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product and Solutions Table 57. RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 58. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) by Players (2019-2021) Table 59. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Players (2019-2021) Table 60. Breakdown of Devic's Syndrome (Neuromyelitis Optica) Treatment by Company Type (Tier 1, Tier 2 and Tier 3) Table 61. Devic's Syndrome (Neuromyelitis Optica) Treatment Players Head Office, Products and Services Provided Table 62. Devic's Syndrome (Neuromyelitis Optica) Treatment Mergers & Acquisitions in the Past Five Years Table 63. Devic's Syndrome (Neuromyelitis Optica) Treatment New Entrants and Expansion Plans Table 64. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) by Type (2016-2021) Table 65. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Type (2016-2021) Table 66. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Forecast by Type (2021-2026) Table 67. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2021) Table 68. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Forecast by Application (2021-2026) Table 69. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2021) & (USD Million) Table 70. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2021-2026) & (USD Million) Table 71. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2021) & (USD Million) Table 72. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2021-2026) & (USD Million) Table 73. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2016-2021) & (USD Million) Table 74. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2021-2026) & (USD Million) Table 75. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2021) & (USD Million) Table 76. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2021-2026) & (USD Million) Table 77. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2021) & (USD Million) Table 78. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2021-2026) & (USD Million) Table 79. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2016-2021) & (USD Million) Table 80. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2021-2026) & (USD Million) Table 81. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2021) & (USD Million) Table 82. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2021-2026) & (USD Million) Table 83. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2021) & (USD Million) Table 84. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2021-2026) & (USD Million) Table 85. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Region (2016-2021) & (USD Million) Table 86. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Region (2021-2026) & (USD Million) Table 87. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2021) & (USD Million) Table 88. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2021-2026) & (USD Million) Table 89. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2021) & (USD Million) Table 90. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2021-2026) & (USD Million) Table 91. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2016-2021) & (USD Million) Table 92. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2021-2026) & (USD Million) Table 93. Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2016-2021) & (USD Million) Table 94. Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2021-2026) & (USD Million) Table 95. Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2016-2021) & (USD Million) Table 96. Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2021-2026) & (USD Million) Table 97. Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2016-2021) & (USD Million) Table 98. Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2021-2026) & (USD Million) List of Figures Figure 1. Devic's Syndrome (Neuromyelitis Optica) Treatment Picture Figure 2. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type in 2020 Figure 3. Eculizumab Figure 4. Methylprednisolone Figure 5. Azathioprine Figure 6. Mycophenolate Mofetil Figure 7. Rituximab Figure 8. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application in 2020 Figure 9. Hospitals Picture Figure 10. Clinic Picture Figure 11. Others Picture Figure 12. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026 Figure 13. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Forecast (2016-2026) & (USD Million) Figure 14. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Region (2016-2026) Figure 15. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Region in 2020 Figure 16. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2016-2026) Figure 17. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2016-2026) Figure 18. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2016-2026) Figure 19. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2016-2026) Figure 20. Middle East and Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2016-2026) Figure 21. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Drivers Figure 22. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Restraints Figure 23. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Trends Figure 24. Alexion Pharmaceuticals, Inc. Recent Developments and Future Plans Figure 25. Teva Pharmaceuticals Recent Developments and Future Plans Figure 26. Fresenius Kabi AG Recent Developments and Future Plans Figure 27. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Developments and Future Plans Figure 28. Lupin Ltd. Recent Developments and Future Plans Figure 29. Sagent Pharmaceuticals, Inc. Recent Developments and Future Plans Figure 30. Zydus Pharmaceuticals, Inc. Recent Developments and Future Plans Figure 31. Sandoz Inc. (Novartis) Recent Developments and Future Plans Figure 32. Alkem Laboratories Ltd. Recent Developments and Future Plans Figure 33. Mylan Pharmaceuticals, Inc. Recent Developments and Future Plans Figure 34. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Developments and Future Plans Figure 35. MedImmune LLC Recent Developments and Future Plans Figure 36. RemeGen, Ltd. Recent Developments and Future Plans Figure 37. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Players in 2020 Figure 38. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) Figure 39. Global Top 3 Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share in 2020 Figure 40. Global Top 10 Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share in 2020 Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021) Figure 42. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Type in 2020 Figure 43. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share Forecast by Type (2021-2026) Figure 44. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Application in 2020 Figure 45. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share Forecast by Application (2021-2026) Figure 46. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2016-2026) Figure 47. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2016-2026) Figure 48. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Country (2016-2026) Figure 49. United States Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 50. Canada Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 51. Mexico Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 52. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2016-2026) Figure 53. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2016-2026) Figure 54. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Country (2016-2026) Figure 55. Germany Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 56. France Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 57. United Kingdom Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 58. Russia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 59. Italy Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 60. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2016-2026) Figure 61. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2016-2026) Figure 62. Asia-Pacific Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Region (2016-2026) Figure 63. China Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 64. Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 65. South Korea Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 66. India Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 67. Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 68. Australia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 69. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2016-2026) Figure 70. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2016-2026) Figure 71. South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Country (2016-2026) Figure 72. Brazil Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 73. Argentina Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 74. Middle East and Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2016-2026) Figure 75. Middle East and Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2016-2026) Figure 76. Middle East and Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Country (2016-2026) Figure 77. Turkey Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 78. Saudi Arabia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 79. UAE Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2016-2026) & (USD Million) Figure 80. Methodology Figure 81. Research Process and Data Source

Qualitative Analysis covers:

  • Industry Status and Trends
  • Manufacturer/Company profiles, manufacturing base distribution, sales areas, product introduction, main business, market position and their competitors.
  • Product Development, Technology, Price, Cost, Manufacturing Process and Trends
  • Market segment by regions, types, applications and forecast
  • Market opportunities, potential, government policies and influence factors.
     

Quantitative Analysis covers:

  • Market size (value, sales/output, historical data and forecasts)
  • Sales/output/capacity, revenue, price, gross margin, market share, for top players. Through interviewing each manufacturers,  distributors, traders, dealers and buyers etc.
  • Cost structure, proportion, price trend, gross margin and trend, status and trend, for 10 years
  • Market size by types, regions, applications for 10 years
  • Market forecast based on the potential demand from downstream clients/buyers, government, influence factors and the total economic indication, maybe occur in following years.
     

Data Sources:

Methodology

 

Publisher: GlobalInfoResearch
Chat with us